In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.
Exact Sciences is facing a barrage of headwinds. The company's financial results haven't been good of late.
The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected to continue expanding, with projections indicating it could reach approximately $390.65 billion, growing at a compound annual growth rate (CAGR) of around 8.20% from 2024 to 2030.
We are almost halfway through 2024, and the stock market is putting on a masterclass performance. The S&P 500 is up 12% year-to-date after rising 23% last year.
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.
Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.
With the S&P 500 sitting just a few points below setting a new all-time high, the bull market that began in 2022 is still snorting. Although a correction or even a bear market will eventually happen, the market is content to run higher.
The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.